Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) or programmed cell death-1 (PD-1) pathways are reshaping the landscape of cancer therapy, yielding unprecedented clinical success in treating multiple cancer types [1]. This evidence concerns the gene PDCD1 and cancer.